Close Menu

NEW YORK (GenomeWeb) – 23andMe today announced it has raised $115 million in a Series E financing round that will go toward expanding the company's operations and "maximize the potential of its direct-to-consumer product in the US and abroad." 

Fidelity Management & Research led the financing and was joined by new investors Casdin Capital, WuXi Healthcare Ventures, and Xfund. Existing investors Illumina, New Enterprise Associates, MPM Capital, and Google Ventures also participated in the round. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.